Hematology

FDA grants priority review to ide-cel for multiple myeloma

The U.S. Food and Drug Administration has granted priority review to idecabtagene vicleucel ((ide-cel; Bristol Myers Squibb, bluebird bio) for the treatment of patients with multiple myeloma who have received ≥3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, according to a press release. The...